Search for "pyridone" in Full Text gives 42 result(s) in Beilstein Journal of Organic Chemistry.
Beilstein J. Org. Chem. 2025, 21, 327–339, doi:10.3762/bjoc.21.23
Graphical Abstract
Figure 1: Chemical structures of compounds 1–6, prototenellin D and pretenellin B [7].
Figure 2: Key 1H-1H COSY, HMBC and ROESY correlations of 1.
Figure 3: Comparison of experimental (black) and simulated Boltzmann-averaged (red: (2’S,3’S,12S)-1; green: (...
Figure 4: A plausible biosynthetic pathway of 1–3.
Figure 5: Biofilm inhibition and eradication assessment via CV staining assay. A) S. aureus biofilm inhibitio...
Figure 6: A) Metabolic activity in biomass of S. aureus biofilm treated with farinosones D (1) or A (2). Erro...
Beilstein J. Org. Chem. 2024, 20, 3290–3298, doi:10.3762/bjoc.20.273
Graphical Abstract
Figure 1: Examples of important azafluoranthene and benzo[j]fluoranthene natural products, and acenaphthylene...
Scheme 1: Selected synthetic strategies towards heterocyclic fluoranthene analogues, and our approach.
Scheme 2: Synthesis of benzo[j]fluoranthene 18.
Scheme 3: Synthesis of benzo[j]fluoranthene 23.
Scheme 4: Synthesis of benzo[j]fluoranthene 28.
Beilstein J. Org. Chem. 2024, 20, 2704–2707, doi:10.3762/bjoc.20.227
Beilstein J. Org. Chem. 2024, 20, 2599–2607, doi:10.3762/bjoc.20.219
Graphical Abstract
Figure 1: Derivatives of 6-methyluracil and 2-hydroxypyridine demonstrating pharmacological activity: 5-hydro...
Scheme 1: Peroxydisulfate oxidation of 6-methyluracil and 1,3,6-trimethyluracil. Сonditions: a) (NH4)2S2O8, 2...
Scheme 2: Peroxydisulfate oxidation of pyridine and 2-hydroxypyridine. Сonditions: a) (NH4)2S2O8, 24% NaOH, 4...
Scheme 3: Potential mechanism of peroxydisulfate oxidation of 6-methyluracil and 1,3,6-trimethyluracil.
Beilstein J. Org. Chem. 2024, 20, 1453–1461, doi:10.3762/bjoc.20.128
Graphical Abstract
Figure 1: Representative pyrazoles with pharmacological activities and S/Se-containing pharmaceutical molecul...
Scheme 1: Approaches for thio/selenocyanation of the pyrazole skeleton.
Scheme 2: PhICl2/NH4SCN-mediated thiocyanation of pyrazoles. Reaction conditions: under N2 atmosphere, a mixt...
Scheme 3: PhICl2/KSeCN-mediated selenocyanation of pyrazoles. Reaction conditions: under N2 atmosphere, a mix...
Scheme 4: Gram-scale synthesis of compounds 2a and 3a and their derivatization.
Scheme 5: Plausible reaction mechanism.
Beilstein J. Org. Chem. 2024, 20, 1029–1036, doi:10.3762/bjoc.20.91
Graphical Abstract
Figure 1: Structure of HeE1-2Tyr (1) and of the derivatives synthesized in this work.
Scheme 1: Synthetic pathway to benzoxazole analogue 2 of HeE1-2Tyr (1). Reagents and conditions: a) TMSN3, Tf...
Scheme 2: Synthetic pathway to pyridone derivatives 3a–c of HeE1-2Tyr (1). Reagents and conditions: a) MeI, K2...
Scheme 3: Synthetic pathway to thiazolopyridone derivatives 4a,b of HeE1-2Tyr (1). Reagents and conditions: a...
Figure 2: Analysis of inhibitory activity against SARS-CoV-2 RdRp using primer extension assay. A) Gel-based ...
Beilstein J. Org. Chem. 2024, 20, 479–496, doi:10.3762/bjoc.20.43
Graphical Abstract
Scheme 1: Proposed mechanism and observation of alkylgold intermediates.
Figure 1: First order alkene decay for urea alkene 1a (0.05 M) hydroamination with [JPhosAu(NCCH3)]SbF6 (5, 2...
Figure 2: Cooperative effect of mixed CD2Cl2/MeOH on alkene 1a → 3a conversion with catalyst 5 (2.5 mol %). E...
Figure 3: Different additive impact on rate of 1a → 3a depending upon catalyst and co-solvent. The data for J...
Figure 4: (a) Schematic for synthesis of [L–Au–L]SbF6 where L = JPhos. (b) Perspective drawing of the cation ...
Figure 5: (a) kobs for reaction of urea 1a (0.05 M) in DCM with catalyst 5 and titrated CH3OH/CH3OD. Data for...
Figure 6: Rate of urea 1a (0.05 M) hydroamination with JPhosAu(NCCH3)SbF6 (2.5 mol %) in CH2Cl2 with 5, 25, a...
Figure 7: Observed rates for the reaction of carbamate 1b (0.03–0.24 M) with JackiephosAuNTf2 (0.0013 M, 6a) ...
Figure 8: Influence of catalyst 5 concentration on rate of 1a (0.05 M in CH2Cl2 with 0, 10 μL MeOH). Error ba...
Scheme 2: Proposed alternate mechanism.
Beilstein J. Org. Chem. 2022, 18, 1203–1209, doi:10.3762/bjoc.18.125
Graphical Abstract
Scheme 1: a) Mechanochemical synthesis of g-PCN from sodium phosphide and trichlorotriazine (previous work [38]) ...
Figure 1: PXRD patterns of g-h-PCN (green) and g-h-PCN300 (teal).
Figure 2: XPS scans of a) C 1s, b) N 1s and c) P 2p for the pre-annealed g-h-PCN and d) C 1s, e) N 1s and f) ...
Figure 3: 31P MAS NMR of a) g-h-PCN and b) g-h-PCN300. Asterisks denote spinning sidebands.
Figure 4: Calculated structures for a) corrugated (edge facing), b) corrugated (single layer), c) layered g-h...
Beilstein J. Org. Chem. 2022, 18, 1188–1194, doi:10.3762/bjoc.18.123
Graphical Abstract
Scheme 1: Different strategies for phospha-Brook reactions.
Scheme 2: Scope of 1 (secondary phosphine oxides and phosphonate). Reaction conditions: 1 (0.2 mmol), 2-pyrid...
Scheme 3: Scope of 2 (α-pyridinealdehydes and α-pyridones). Reaction conditions: diphenylphosphine oxide (1a,...
Scheme 4: Control experiments.
Scheme 5: Proposed mechanism.
Beilstein J. Org. Chem. 2022, 18, 738–745, doi:10.3762/bjoc.18.74
Graphical Abstract
Scheme 1: Approaches to the synthesis of alkyl 4-oxo-1,4-dihydropyridine-3-carboxylates.
Scheme 2: Synthesis of 4-oxo-1,4-dihydropyridine-3-carboxylates.
Scheme 3: Synthesis of Isoxazoles 11–13.
Scheme 4: Synthesis of isoxazoles 1.
Scheme 5: Synthesis of pyridones 2.
Scheme 6: Transformations of pyridones 2.
Beilstein J. Org. Chem. 2021, 17, 2488–2495, doi:10.3762/bjoc.17.165
Graphical Abstract
Scheme 1: 3d-Transition-metal-catalyzed C–H functionalization to access functionalized ferrocenes.
Scheme 2: Scope of ferrocenes with morpholine.
Scheme 3: Scope of various amines with 1a.
Scheme 4: Synthetic applications.
Scheme 5: Mechanistic experiments.
Beilstein J. Org. Chem. 2021, 17, 1752–1813, doi:10.3762/bjoc.17.123
Graphical Abstract
Scheme 1: Fluorination with N-F amine 1-1.
Scheme 2: Preparation of N-F amine 1-1.
Scheme 3: Reactions of N-F amine 1-1.
Scheme 4: Synthesis of N-F perfluoroimides 2-1 and 2-2.
Scheme 5: Synthesis of 1-fluoro-2-pyridone (3-1).
Scheme 6: Fluorination with 1-fluoro-2-pyridone (3-1).
Figure 1: Synthesis of N-F sulfonamides 4-1a–g.
Scheme 7: Fluorination with N-F reagent 4-1b,c,f.
Scheme 8: Fluorination of alkenyllithiums with N-F 4-1h.
Scheme 9: Synthesis of N-fluoropyridinium triflate (5-4a).
Scheme 10: Synthetic methods for N-F-pyridinium salts.
Figure 2: Synthesis of various N-fluoropyridinium salts. Note: athis yield was the one by the improved method...
Scheme 11: Fluorination power order of N-fluoropyridinium salts.
Scheme 12: Fluorinations with N-F salts 5-4.
Scheme 13: Fluorination of Corey lactone 5-7 with N-F-bis(methoxymethyl) salt 5-4l.
Scheme 14: Fluorination with NFPy.
Scheme 15: Synthesis of the N-F reagent, N-fluoroquinuclidinium fluoride (6-1).
Scheme 16: Fluorinations achieved with N-F fluoride 6-1.
Scheme 17: Synthesis of N-F imides 7-1a–g.
Scheme 18: Fluorination with (CF3SO2)2NF, 7-1a.
Scheme 19: Fluorination reactions of various substrates with 7-1a.
Scheme 20: Synthesis of N-F triflate 8-1.
Scheme 21: Synthesis of chiral N-fluoro sultams 9-1 and 9-2.
Scheme 22: Fluorination with chiral N-fluoro sultams 9-1 and 9-2.
Scheme 23: Synthesis of saccharin-derived N-fluorosultam 10-2.
Scheme 24: Fluorination with N-fluorosultam 10-2.
Scheme 25: Synthesis of N-F reagent 11-2.
Scheme 26: Fluorination with N-F reagent 11-2.
Scheme 27: Synthesis and reaction of N-fluorolactams 12-1.
Scheme 28: Synthesis of NFOBS 13-2.
Scheme 29: Fluorination with NFOBS 13-2.
Scheme 30: Synthesis of NFSI (14-2).
Scheme 31: Fluorination with NFSI 14-2.
Scheme 32: Synthesis of N-fluorosaccharin (15-1) and N-fluorophthalimide (15-2).
Scheme 33: Synthesis of N-F salts 16-3.
Scheme 34: Fluorination with N-F salts 16-3.
Figure 3: Monofluorination with Selectfluor (16-3a).
Figure 4: Difluorination with Selectfluor (16-3a).
Scheme 35: Transfer fluorination of Selectfluor (16-3a).
Scheme 36: Fluorination of substrates with Selectfluor (16-3a).
Scheme 37: Synthesis of chiral N-fluoro-sultam 17-2.
Scheme 38: Asymmetric fluorination with chiral 17-2.
Figure 5: Synthesis of Zwitterionic N-fluoropyridinium salts 18-2a–h.
Scheme 39: Fluorinating power order of zwitterionic N-fluoropyridinium salts.
Scheme 40: Fluorination with zwitterionic 18-2.
Scheme 41: Activation of salt 18-2h with TfOH.
Scheme 42: Synthesis of NFTh, 19-2.
Scheme 43: Fluorination with NFTh, 19-2.
Scheme 44: Synthesis of 3-fluorobenzo-1,2,3-oxathiazin-4-one 2,2-dioxide (20-2).
Scheme 45: Fluorination with 20-2.
Scheme 46: Synthesis of N-F amide 21-3.
Scheme 47: Fluorination with N-F amide 21-2.
Scheme 48: Synthesis of N,N’-difluorodiazoniabicyclo[2.2.2]octane salts 22-1.
Scheme 49: One-pot synthesis of N,N’-difluoro-1,4-diazoniabicyclo[2.2.2]octane bistetrafluoroborate salt (22-1d...
Figure 6: Fluorination of anisole with 22-1a, d, e.
Scheme 50: Fluorination with N,N’-diF bisBF4 22-1d.
Scheme 51: Synthesis of bis-N-F reagents 23-1–5.
Scheme 52: Fluorination with 23-2, 4, 5.
Figure 7: Synthesis of N,N’-difluorobipyridinium salts 24-2.
Figure 8: Controlled fluorination of N,N’-diF 24-2.
Scheme 53: Fluorinating power of N,N’-diF salts 24-2 and N-F salt 5-4a.
Scheme 54: Fluorination reactions with SynfluorTM (24-2b).
Scheme 55: Additional fluorination reactions with SynfluorTM (24-2b).
Scheme 56: Synthesis of N-F 25-1.
Scheme 57: Fluorination of polycyclic aromatics with 25-1.
Scheme 58: Synthesis of 26-1 and dimethyl analog 26-2.
Scheme 59: Fluorination with reagents 26-1, 26-2, 1-1, and 26-3.
Scheme 60: Synthesis of N-F reagent 27-2.
Scheme 61: Synthesis of chiral N-F reagents 27-6.
Scheme 62: Synthesis of chiral N-F 27-7–9.
Scheme 63: Asymmetric fluorination with 27-6.
Scheme 64: Synthesis of chiral N-F reagents 28-3.
Scheme 65: Asymmetric fluorination with 28-3.
Scheme 66: Synthesis of chiral N-F reagents 28-7.
Figure 9: Asymmetric fluorination with 28-7.
Scheme 67: In situ formation of N-fluorinated cinchona alkaloids with SelectfluorTM.
Scheme 68: Asymmetric fluorination with N-F alkaloids formed in situ.
Scheme 69: Synthesis of N-fluorocinchona alkaloids with Selectfluor.
Scheme 70: Asymmetric fluorination with 30-1–4.
Scheme 71: Transfer fluorination from various N-F reagents.
Figure 10: Asymmetric fluorination of silyl enol ethers.
Scheme 72: Synthesis of N-fluoro salt 32-2.
Scheme 73: Reactivity of N-fluorotriazinium salt 32-2.
Scheme 74: Synthesis of bulky N-fluorobenzenesulfonimide NFBSI 33-3.
Scheme 75: Comparison of NFSI and NFBSI.
Scheme 76: Synthesis of p-substituted N-fluorobenzenesulfonimides 34-3.
Figure 11: Asymmetric fluorination with 34-3 and a chiral catalyst 34-4.
Scheme 77: 1,4-Fluoroamination with Selecfluor and a chiral catalyst.
Figure 12: Asymmetric fluoroamination with 35-5a, b.
Scheme 78: Synthesis of Selectfluor analogs 35-5a, b.
Scheme 79: Synthesis of chiral dicationic DABCO-based N-F reagents 36-5.
Scheme 80: Asymmetric fluorocyclization with chiral 36-5b.
Scheme 81: Synthesis of chiral 37-2a,b.
Scheme 82: Asymmetric fluorination with chiral 37-2a,b.
Scheme 83: Asymmetric fluorination with chiral 37-2b.
Scheme 84: Reaction of indene with chiral 37-2a,b.
Scheme 85: Synthesis of Me-NFSI, 38-2.
Scheme 86: Fluorination of active methine compounds with Me-NFSI.
Scheme 87: Fluorination of malonates with Me-NFSI.
Scheme 88: Fluorination of keto esters with Me-NFSI.
Scheme 89: Synthesis of N-F 39-3 derived from the ethylene-bridged Tröger’s base.
Scheme 90: Fluorine transfer from N-F 39-3.
Scheme 91: Fluorination with N-F 39-3.
Scheme 92: Synthesis of SelectfluorCN.
Scheme 93: Bistrifluoromethoxylation of alkenes using SelectfluorCN.
Figure 13: Synthesis of NFAS 41-2.
Scheme 94: Radical fluorination with different N-F reagents.
Scheme 95: Radical fluorination of alkenes with NFAS 41-2.
Scheme 96: Radical fluorination of alkenes with NFAS 41-2f.
Scheme 97: Decarboxylative fluorination with NFAS 41-2a,f.
Scheme 98: Fluorine plus detachment (FPD).
Figure 14: FPD values of representative N-F reagents in CH2Cl2 and CH3CN (in parentheses). Adapted with permis...
Scheme 99: N-F homolytic bond dissociation energy (BDE).
Figure 15: BDE values of representative N-F reagents in CH3CN. Adapted with permission from ref. [127]. Copyright 2...
Figure 16: Quantitative reactivity scale for popular N-F reagents. Adapted with permission from ref. [138], publish...
Scheme 100: SET and SN2 mechanisms.
Scheme 101: Radical clock reactions.
Scheme 102: Reaction of potassium enolate of citronellic ester with N-F reagents, 10-1, NFSI, and 8-1.
Scheme 103: Reaction of compound IV with Selectfluor (OTf) and NFSI.
Scheme 104: Reaction of TEMPO with Selecfluor.
Beilstein J. Org. Chem. 2021, 17, 1335–1351, doi:10.3762/bjoc.17.93
Graphical Abstract
Figure 1: Icilio Guareschi (1847–1918). (Source: Annali della Reale Accademia di Agricoltura di Torino 1919, ...
Scheme 1: Vitamin B6 (pyridoxine, 1), gabapentin (2), and thymol (3).
Figure 2: Baliatico (Nursing) by Francesco Scaramuzza (275 cm × 214 cm, Parma, Complesso Museale della Pilott...
Figure 3: Schiff’s fictitious report on the foundation of the Gazzetta Chimica Italiana (Image reproduced fro...
Scheme 2: Reaction of thymol (3) with chloroform under the basic conditions of the Guareschi–Lustgarten react...
Figure 4: The chemistry building of Turin University in a historical picture. Note, that one of the “mysterio...
Scheme 3: Triacetonamine (6) and the related compounds phorone (7), α-eucaine (8), and tropinone (9).
Scheme 4: Taxonomy of the Guareschi pyridone syntheses.
Scheme 5: The catalytic cycle of the “1897 reaction”.
Scheme 6: Resonance forms of the radical 10.
Figure 5: The wet chamber used by Guareschi to restore parchments (Gorrini, G. L'incendio della R. Biblioteca...
Figure 6: The Guareschi mask. (Servizio Chimico Militare. L'opera di Icilio Guareschi precursore della masche...
Figure 7: Guareschi’s bust at the Dipartimento di Scienza e Tecnologia del Farmaco of Turin University. Permi...
Beilstein J. Org. Chem. 2021, 17, 819–865, doi:10.3762/bjoc.17.71
Graphical Abstract
Figure 1: Marketed drugs with acridine moiety.
Scheme 1: Synthesis of 4-arylacridinediones.
Scheme 2: Proposed mechanism for acridinedione synthesis.
Scheme 3: Synthesis of tetrahydrodibenzoacridinones.
Scheme 4: Synthesis of naphthoacridines.
Scheme 5: Plausible mechanism for naphthoacridines.
Figure 2: Benzoazepines based potent molecules.
Scheme 6: Synthesis of azepinone.
Scheme 7: Proposed mechanism for azepinone formation.
Scheme 8: Synthesis of benzoazulenen-1-one derivatives.
Scheme 9: Proposed mechanism for benzoazulene-1-one synthesis.
Figure 3: Indole-containing pharmacologically active molecules.
Scheme 10: Synthesis of functionalized indoles.
Scheme 11: Plausible mechanism for the synthesis of functionalized indoles.
Scheme 12: Synthesis of spirooxindoles.
Scheme 13: Synthesis of substituted spirooxindoles.
Scheme 14: Plausible mechanism for the synthesis of substituted spirooxindoles.
Scheme 15: Synthesis of pyrrolidinyl spirooxindoles.
Scheme 16: Proposed mechanism for pyrrolidinyl spirooxindoles.
Figure 4: Pyran-containing biologically active molecules.
Scheme 17: Synthesis of functionalized benzopyrans.
Scheme 18: Plausible mechanism for synthesis of benzopyran.
Scheme 19: Synthesis of indoline-spiro-fused pyran derivatives.
Scheme 20: Proposed mechanism for indoline-spiro-fused pyran.
Scheme 21: Synthesis of substituted naphthopyrans.
Figure 5: Marketed drugs with pyrrole ring.
Scheme 22: Synthesis of tetra-substituted pyrroles.
Scheme 23: Mechanism for silica-supported PPA-SiO2-catalyzed pyrrole synthesis.
Scheme 24: Synthesis of pyrrolo[1,10]-phenanthrolines.
Scheme 25: Proposed mechanism for pyrrolo[1,10]-phenanthrolines.
Figure 6: Marketed drugs and molecules containing pyrimidine and pyrimidinones skeletons.
Scheme 26: MWA-MCR pyrimidinone synthesis.
Scheme 27: Two proposed mechanisms for pyrimidinone synthesis.
Scheme 28: MWA multicomponent synthesis of dihydropyrimidinones.
Scheme 29: Proposed mechanism for dihydropyrimidinones.
Figure 7: Biologically active fused pyrimidines.
Scheme 30: MWA- MCR for the synthesis of pyrrolo[2,3-d]pyrimidines.
Scheme 31: Proposed mechanism for pyrrolo[2,3-d]pyrimidines.
Scheme 32: Synthesis of substituted pyrrolo[2,3-d]pyrimidine-2,4-diones.
Scheme 33: Probable pathway for pyrrolo[2,3-d]pyrimidine-2,4-diones.
Scheme 34: Synthesis of pyridopyrimidines.
Scheme 35: Plausible mechanism for the synthesis of pyridopyrimidines.
Scheme 36: Synthesis of dihydropyridopyrimidine and dihydropyrazolopyridine.
Scheme 37: Proposed mechanism for the formation of dihydropyridopyrimidine.
Scheme 38: Synthesis of thiopyrano[4,3-d]pyrimidines.
Scheme 39: Plausible mechanism for the synthesis of thiopyrano[4,3-d]pyrimidines.
Scheme 40: Synthesis of decorated imidazopyrimidines.
Scheme 41: Proposed mechanism for imidazopyrimidine synthesis.
Figure 8: Pharmacologically active molecules containing purine bases.
Scheme 42: Synthesis of aza-adenines.
Scheme 43: Synthesis of 5-aza-7-deazapurines.
Scheme 44: Proposed mechanism for deazapurines synthesis.
Figure 9: Biologically active molecules containing pyridine moiety.
Scheme 45: Synthesis of steroidal pyridines.
Scheme 46: Proposed mechanism for steroidal pyridine.
Scheme 47: Synthesis of N-alkylated 2-pyridones.
Scheme 48: Two possible mechanisms for pyridone synthesis.
Scheme 49: Synthesis of pyridone derivatives.
Scheme 50: Postulated mechanism for synthesis of pyridone.
Figure 10: Biologically active fused pyridines.
Scheme 51: Benzimidazole-imidazo[1,2-a]pyridines synthesis.
Scheme 52: Mechanism for the synthesis of benzimidazole-imidazo[1,2-a]pyridines.
Scheme 53: Synthesis of pyrazolo[3,4-b]pyridine-5-spirocycloalkanedione derivatives.
Scheme 54: Proposed mechanism for spiro-pyridines.
Scheme 55: Functionalized macrocyclane-fused pyrazolo[3,4-b]pyridine derivatives.
Scheme 56: Mechanism postulated for macrocyclane-fused pyrazolo[3,4-b]pyridine.
Scheme 57: Generation of pyrazolo[3,4-b]pyridines.
Scheme 58: Proposed mechanism for the synthesis of pyrazolo[3,4-b]pyridines.
Scheme 59: Proposed mechanism for the synthesis of azepinoindole.
Figure 11: Pharmaceutically important molecules with quinoline moiety.
Scheme 60: Povarov-mediated quinoline synthesis.
Scheme 61: Proposed mechanism for Povarov reaction.
Scheme 62: Synthesis of pyrazoloquinoline.
Scheme 63: Plausible mechanism for pyrazoloquinoline synthesis.
Figure 12: Quinazolinones as pharmacologically significant scaffolds.
Scheme 64: Four-component reaction for dihydroquinazolinone.
Scheme 65: Proposed mechanism for dihydroquinazolinones.
Scheme 66: Synthesis purine quinazolinone and PI3K-δ inhibitor.
Scheme 67: Synthesis of fused benzothiazolo/benzoimidazoloquinazolinones.
Scheme 68: Proposed mechanism for fused benzothiazolo/benzoimidazoloquinazolinones.
Scheme 69: On-water reaction for synthesis of thiazoloquinazolinone.
Scheme 70: Proposed mechanism for the thiazoloquinazolinone synthesis.
Scheme 71: β-Cyclodextrin-mediated synthesis of indoloquinazolinediones.
Scheme 72: Proposed mechanism for synthesis of indoloquinazolinediones.
Figure 13: Triazoles-containing marketted drugs and pharmacologically active molecules.
Scheme 73: Cu(I) DAPTA-catalyzed 1,2,3-triazole formation.
Scheme 74: Mechanism for Cu(I) DAPTA-catalyzed triazole formation.
Scheme 75: Synthesis of β-hydroxy-1,2,3-triazole.
Scheme 76: Proposed mechanism for synthesis of β-hydroxy-1,2,3-triazoles.
Scheme 77: Synthesis of bis-1,2,4-triazoles.
Scheme 78: Proposed mechanism for bis-1,2,4-triazoles synthesis.
Figure 14: Thiazole containing drugs.
Scheme 79: Synthesis of a substituted thiazole ring.
Scheme 80: Synthesis of pyrazolothiazoles.
Figure 15: Chromene containing drugs.
Scheme 81: Magnetic nanocatalyst-mediated aminochromene synthesis.
Scheme 82: Proposed mechanism for the synthesis of chromenes.
Beilstein J. Org. Chem. 2020, 16, 1489–1494, doi:10.3762/bjoc.16.124
Graphical Abstract
Figure 1: Structures of compounds 1–5.
Figure 2: COSY-deduced spin-system (bold lines) and key HMBC correlations (arrows) for compound 1, and struct...
Figure 3: Extinction of luminol chemiluminescence by 1.
Beilstein J. Org. Chem. 2020, 16, 1006–1021, doi:10.3762/bjoc.16.90
Graphical Abstract
Scheme 1: Copper-catalysed ACA of organometallics to piperidones. A) addition of organozinc reagents; B) addi...
Scheme 2: Copper-catalysed ACA of alkenylalanes to N-substituted-2,3-dehydro-4-piperidones.
Scheme 3: Copper-catalysed asymmetric addition of dialkylzinc reagents to N-acyl-4-methoxypyridinium salts fo...
Scheme 4: Copper-catalysed ACA of organozirconium reagents to N-substituted 2,3-dehydro-4-piperidones and lac...
Scheme 5: Copper-catalysed ACA of Grignard reagents to chromones and coumarins and further derivatisation of ...
Scheme 6: Copper-catalysed ACA of Grignard reagents to N-protected quinolones.
Scheme 7: Copper-catalysed ACAs of organometallics to conjugated unsaturated lactams.
Scheme 8: Copper-catalysed ACA of Et2Zn to 5,6-dihydro-2-pyranone.
Scheme 9: Copper-catalysed ACA of Grignard reagents to pyranone and 5,6-dihydro-2-pyranone.
Scheme 10: Copper-catalysed AAA of an organozirconium reagent to heterocyclic acceptors.
Scheme 11: Copper-catalysed ring opening of an oxygen-bridged substrate with trialkylaluminium reagents.
Scheme 12: Copper-catalysed ring opening of oxabicyclic substrates with organolithium reagents (selected examp...
Scheme 13: Copper-catalysed ring opening of polycyclic meso hydrazines.
Scheme 14: Copper-catalysed ACA of Grignard reagents to alkenyl-substituted aromatic N-heterocycles.
Scheme 15: Copper-catalysed ACA of Grignard reagents to β-substituted alkenylpyridines.
Scheme 16: Copper-catalysed ACA of organozinc reagents to alkylidene Meldrum’s acids.
Beilstein J. Org. Chem. 2019, 15, 2840–2846, doi:10.3762/bjoc.15.277
Graphical Abstract
Scheme 1: General synthetic pathway to 1.
Scheme 2: Synthesis of acetamides 2.
Scheme 3: Possible reaction pathways for the formation of enaminone 7.
Scheme 4: Possible reaction pathways for the formation of pyrrolo[3,4-b]pyridin-5-one derivatives 1.
Figure 1: View of the structure of 1e in the crystal (CCDC: 1921613). Thermal ellipsoids indicate 50% probabi...
Scheme 5: Tautomeric equilibrium of pyrrolo[3,4-b]pyridin-5-one derivatives 1 in solution.
Beilstein J. Org. Chem. 2019, 15, 2486–2492, doi:10.3762/bjoc.15.241
Graphical Abstract
Scheme 1: Structures of tetraisobutylpyridine[4]arene 1 and tetraisobutylresorcin[4]arene 2.
Figure 1: Spectra of 1 + Me4NPF6 1:3 in acetone in a) (+)ESI-MS and b) (−)ESI-MS. Insets showing arrival time...
Figure 2: (+)ESI-MS profile spectrum of the mixture of 1, 2 and TMAPF6 in acetonitrile (20 µM, 1:1:1). Inset ...
Figure 3: Calculated ESP surfaces (in au) superimposed on the total electron density (0.004 au) for 1 and 2: ...
Beilstein J. Org. Chem. 2019, 15, 2447–2457, doi:10.3762/bjoc.15.237
Graphical Abstract
Figure 1: Bioactive molecules containing a tetrazole, pyridone or isoquinolone ring.
Scheme 1: Approaches for the synthesis of tetrazoles and isoquinolones and their interplay as designed in thi...
Scheme 2: Scope of the Ugi-azide-4CR/deprotection/acylation sequence. Ugi-azide-4CR conducted at the 2.0 mmol...
Scheme 3: Influence of substituents R and R2 on the reaction outcome. For compounds 4k–m the overall yield in...
Scheme 4: Influence of the alkyne and R1 substituent on the reaction outcome.
Scheme 5: Scope of acrylic, heterocyclic and ring-fused N-acylaminomethyl tetrazole substrates.
Scheme 6: Proposed reaction mechanism using substrates 1a and 3a.
Beilstein J. Org. Chem. 2019, 15, 1612–1704, doi:10.3762/bjoc.15.165
Graphical Abstract
Figure 1: Various drugs having IP nucleus.
Figure 2: Participation percentage of various TMs for the syntheses of IPs.
Scheme 1: CuI–NaHSO4·SiO2-catalyzed synthesis of imidazo[1,2-a]pyridines.
Scheme 2: Experimental examination of reaction conditions.
Scheme 3: One-pot tandem reaction for the synthesis of 2-haloimidazopyridines.
Scheme 4: Mechanistic scheme for the synthesis of 2-haloimidazopyridine.
Scheme 5: Copper-MOF-catalyzed three-component reaction (3-CR) for imidazo[1,2-a]pyridines.
Scheme 6: Mechanism for copper-MOF-driven synthesis.
Scheme 7: Heterogeneous synthesis via titania-supported CuCl2.
Scheme 8: Mechanism involving oxidative C–H functionalization.
Scheme 9: Heterogeneous synthesis of IPs.
Scheme 10: One-pot regiospecific synthesis of imidazo[1,2-a]pyridines.
Scheme 11: Vinyl azide as an unprecedented substrate for imidazo[1,2-a]pyridines.
Scheme 12: Radical pathway.
Scheme 13: Cu(I)-catalyzed transannulation approach for imidazo[1,5-a]pyridines.
Scheme 14: Plausible radical pathway for the synthesis of imidazo[1,5-a]pyridines.
Scheme 15: A solvent-free domino reaction for imidazo[1,2-a]pyridines.
Scheme 16: Cu-NPs-mediated synthesis of imidazo[1,2-a]pyridines.
Scheme 17: CuI-catalyzed synthesis of isoxazolylimidazo[1,2-a]pyridines.
Scheme 18: Functionalization of 4-bromo derivative via Sonogashira coupling reaction.
Scheme 19: A plausible reaction pathway.
Scheme 20: Cu(I)-catalyzed intramolecular oxidative C–H amidation reaction.
Scheme 21: One-pot synthetic reaction for imidazo[1,2-a]pyridine.
Scheme 22: Plausible reaction mechanism.
Scheme 23: Cu(OAc)2-promoted synthesis of imidazo[1,2-a]pyridines.
Scheme 24: Mechanism for aminomethylation/cycloisomerization of propiolates with imines.
Scheme 25: Three-component synthesis of imidazo[1,2-a]pyridines.
Figure 3: Scope of pyridin-2(1H)-ones and acetophenones.
Scheme 26: CuO NPS-promoted A3 coupling reaction.
Scheme 27: Cu(II)-catalyzed C–N bond formation reaction.
Scheme 28: Mechanism involving Chan–Lam/Ullmann coupling.
Scheme 29: Synthesis of formyl-substituted imidazo[1,2-a]pyridines.
Scheme 30: A tandem sp3 C–H amination reaction.
Scheme 31: Probable mechanistic approach.
Scheme 32: Dual catalytic system for imidazo[1,2-a]pyridines.
Scheme 33: Tentative mechanism.
Scheme 34: CuO/CuAl2O4/ᴅ-glucose-promoted 3-CCR.
Scheme 35: A tandem CuOx/OMS-2-based synthetic strategy.
Figure 4: Biomimetic catalytic oxidation in the presence of electron-transfer mediators (ETMs).
Scheme 36: Control experiment.
Scheme 37: Copper-catalyzed C(sp3)–H aminatin reaction.
Scheme 38: Reaction of secondary amines.
Scheme 39: Probable mechanistic pathway.
Scheme 40: Coupling reaction of α-azidoketones.
Scheme 41: Probable pathway.
Scheme 42: Probable mechanism with free energy calculations.
Scheme 43: MCR for cyanated IP synthesis.
Scheme 44: Substrate scope for the reaction.
Scheme 45: Reaction mechanism.
Scheme 46: Probable mechanistic pathway for Cu/ZnAl2O4-catalyzed reaction.
Scheme 47: Copper-catalyzed double oxidative C–H amination reaction.
Scheme 48: Application towards different coupling reactions.
Scheme 49: Reaction mechanism.
Scheme 50: Condensation–cyclization approach for the synthesis of 1,3-diarylated imidazo[1,5-a]pyridines.
Scheme 51: Optimized reaction conditions.
Scheme 52: One-pot 2-CR.
Scheme 53: One-pot 3-CR without the isolation of chalcone.
Scheme 54: Copper–Pybox-catalyzed cyclization reaction.
Scheme 55: Mechanistic pathway catalyzed by Cu–Pybox complex.
Scheme 56: Cu(II)-promoted C(sp3)-H amination reaction.
Scheme 57: Wider substrate applicability for the reaction.
Scheme 58: Plausible reaction mechanism.
Scheme 59: CuI assisted C–N cross-coupling reaction.
Scheme 60: Probable reaction mechanism involving sp3 C–H amination.
Scheme 61: One-pot MCR-catalyzed by CoFe2O4/CNT-Cu.
Scheme 62: Mechanistic pathway.
Scheme 63: Synthetic scheme for 3-nitroimidazo[1,2-a]pyridines.
Scheme 64: Plausible mechanism for CuBr-catalyzed reaction.
Scheme 65: Regioselective synthesis of halo-substituted imidazo[1,2-a]pyridines.
Scheme 66: Synthesis of 2-phenylimidazo[1,2-a]pyridines.
Scheme 67: Synthesis of diarylated compounds.
Scheme 68: CuBr2-mediated one-pot two-component oxidative coupling reaction.
Scheme 69: Decarboxylative cyclization route to synthesize 1,3-diarylimidazo[1,5-a]pyridines.
Scheme 70: Mechanistic pathway.
Scheme 71: C–H functionalization reaction of enamines to produce diversified heterocycles.
Scheme 72: A plausible mechanism.
Scheme 73: CuI-promoted aerobic oxidative cyclization reaction of ketoxime acetates and pyridines.
Scheme 74: CuI-catalyzed pathway for the formation of imidazo[1,2-a]pyridine.
Scheme 75: Mechanistic pathway.
Scheme 76: Mechanistic rationale for the synthesis of products.
Scheme 77: Copper-catalyzed synthesis of vinyloxy-IP.
Scheme 78: Regioselective product formation with propiolates.
Scheme 79: Proposed mechanism for vinyloxy-IP formation.
Scheme 80: Regioselective synthesis of 3-hetero-substituted imidazo[1,2-a]pyridines with different reaction su...
Scheme 81: Mechanistic pathway.
Scheme 82: CuI-mediated synthesis of 3-formylimidazo[1,2-a]pyridines.
Scheme 83: Radical pathway for 3-formylated IP synthesis.
Scheme 84: Pd-catalyzed urea-cyclization reaction for IPs.
Scheme 85: Pd-catalyzed one-pot-tandem amination and intramolecular amidation reaction.
Figure 5: Scope of aniline nucleophiles.
Scheme 86: Pd–Cu-catalyzed Sonogashira coupling reaction.
Scheme 87: One-pot amide coupling reaction for the synthesis of imidazo[4,5-b]pyridines.
Scheme 88: Urea cyclization reaction for the synthesis of two series of pyridines.
Scheme 89: Amidation reaction for the synthesis of imidazo[4,5-b]pyridines.
Figure 6: Amide scope.
Scheme 90: Pd NPs-catalyzed 3-component reaction for the synthesis of 2,3-diarylated IPs.
Scheme 91: Plausible mechanistic pathway for Pd NPs-catalyzed MCR.
Scheme 92: Synthesis of chromenoannulated imidazo[1,2-a]pyridines.
Scheme 93: Mechanism for the synthesis of chromeno-annulated IPs.
Scheme 94: Zinc oxide NRs-catalyzed synthesis of imidazo[1,2-a]azines/diazines.
Scheme 95: Zinc oxide-catalyzed isocyanide based GBB reaction.
Scheme 96: Reaction pathway for ZnO-catalyzed GBB reaction.
Scheme 97: Mechanistic pathway.
Scheme 98: ZnO NRs-catalyzed MCR for the synthesis of imidazo[1,2-a]azines.
Scheme 99: Ugi type GBB three-component reaction.
Scheme 100: Magnetic NPs-catalyzed synthesis of imidazo[1,2-a]pyridines.
Scheme 101: Regioselective synthesis of 2-alkoxyimidazo[1,2-a]pyridines catalyzed by Fe-SBA-15.
Scheme 102: Plausible mechanistic pathway for the synthesis of 2-alkoxyimidazopyridine.
Scheme 103: Iron-catalyzed synthetic approach.
Scheme 104: Iron-catalyzed aminooxygenation reaction.
Scheme 105: Mechanistic pathway.
Scheme 106: Rh(III)-catalyzed double C–H activation of 2-substituted imidazoles and alkynes.
Scheme 107: Plausible reaction mechanism.
Scheme 108: Rh(III)-catalyzed non-aromatic C(sp2)–H bond activation–functionalization for the synthesis of imid...
Scheme 109: Reactivity and selectivity of different substrates.
Scheme 110: Rh-catalyzed direct C–H alkynylation by Li et al.
Scheme 111: Suggested radical mechanism.
Scheme 112: Scandium(III)triflate-catalyzed one-pot reaction and its mechanism for the synthesis of benzimidazo...
Scheme 113: RuCl3-assisted Ugi-type Groebke–Blackburn condensation reaction.
Scheme 114: C-3 aroylation via Ru-catalyzed two-component reaction.
Scheme 115: Regioselective synthetic mechanism.
Scheme 116: La(III)-catalyzed one-pot GBB reaction.
Scheme 117: Mechanistic approach for the synthesis of imidazo[1,2-a]pyridines.
Scheme 118: Synthesis of imidazo[1,2-a]pyridine using LaMnO3 NPs under neat conditions.
Scheme 119: Mechanistic approach.
Scheme 120: One-pot 3-CR for regioselective synthesis of 2-alkoxy-3-arylimidazo[1,2-a]pyridines.
Scheme 121: Formation of two possible products under optimization of the catalysts.
Scheme 122: Mechanistic strategy for NiFe2O4-catalyzed reaction.
Scheme 123: Two-component reaction for synthesizing imidazodipyridiniums.
Scheme 124: Mechanistic scheme for the synthesis of imidazodipyridiniums.
Scheme 125: CuI-catalyzed arylation of imidazo[1,2-a]pyridines.
Scheme 126: Mechanism for arylation reaction.
Scheme 127: Cupric acetate-catalyzed double carbonylation approach.
Scheme 128: Radical mechanism for double carbonylation of IP.
Scheme 129: C–S bond formation reaction catalyzed by cupric acetate.
Scheme 130: Cupric acetate-catalyzed C-3 formylation approach.
Scheme 131: Control experiments for signifying the role of DMSO and oxygen.
Scheme 132: Mechanism pathway.
Scheme 133: Copper bromide-catalyzed CDC reaction.
Scheme 134: Extension of the substrate scope.
Scheme 135: Plausible radical pathway.
Scheme 136: Transannulation reaction for the synthesis of imidazo[1,5-a]pyridines.
Scheme 137: Plausible reaction pathway for denitrogenative transannulation.
Scheme 138: Cupric acetate-catalyzed C-3 carbonylation reaction.
Scheme 139: Plausible mechanism for regioselective C-3 carbonylation.
Scheme 140: Alkynylation reaction at C-2 of 3H-imidazo[4,5-b]pyridines.
Scheme 141: Two-way mechanism for C-2 alkynylation of 3H-imidazo[4,5-b]pyridines.
Scheme 142: Palladium-catalyzed SCCR approach.
Scheme 143: Palladium-catalyzed Suzuki coupling reaction.
Scheme 144: Reaction mechanism.
Scheme 145: A phosphine free palladium-catalyzed synthesis of C-3 arylated imidazopyridines.
Scheme 146: Palladium-mediated Buchwald–Hartwig cross-coupling reaction.
Figure 7: Structure of the ligands optimized.
Scheme 147: Palladium acetate-catalyzed direct arylation of imidazo[1,2-a]pyridines.
Scheme 148: Palladium acetate-catalyzed mechanistic pathway.
Scheme 149: Palladium acetate-catalyzed regioselective arylation reported by Liu and Zhan.
Scheme 150: Mechanism for selective C-3 arylation of IP.
Scheme 151: Pd(II)-catalyzed alkenylation reaction with styrenes.
Scheme 152: Pd(II)-catalyzed alkenylation reaction with acrylates.
Scheme 153: A two way mechanism.
Scheme 154: Double C–H activation reaction catalyzed by Pd(OAc)2.
Scheme 155: Probable mechanism.
Scheme 156: Palladium-catalyzed decarboxylative coupling.
Scheme 157: Mechanistic cycle for decarboxylative arylation reaction.
Scheme 158: Ligand-free approach for arylation of imidazo[1,2-a]pyridine-3-carboxylic acids.
Scheme 159: Mechanism for ligandless arylation reaction.
Scheme 160: NHC-Pd(II) complex assisted arylation reaction.
Scheme 161: C-3 arylation of imidazo[1,2-a]pyridines with aryl bromides catalyzed by Pd(OAc)2.
Scheme 162: Pd(II)-catalyzed C-3 arylations with aryl tosylates and mesylates.
Scheme 163: CDC reaction for the synthesis of imidazo[1,2-a]pyridines.
Scheme 164: Plausible reaction mechanism for Pd(OAc)2-catalyzed synthesis of imidazo[1,2-a]pyridines.
Scheme 165: Pd-catalyzed C–H amination reaction.
Scheme 166: Mechanism for C–H amination reaction.
Scheme 167: One-pot synthesis for 3,6-di- or 2,3,6-tri(hetero)arylimidazo[1,2-a]pyridines.
Scheme 168: C–H/C–H cross-coupling reaction of IPs and azoles catalyzed by Pd(II).
Scheme 169: Mechanistic cycle.
Scheme 170: Rh-catalyzed C–H arylation reaction.
Scheme 171: Mechanistic pathway for C–H arylation of imidazo[1,2-a]pyridine.
Scheme 172: Rh(III)-catalyzed double C–H activation of 2-phenylimidazo[1,2-a]pyridines and alkynes.
Scheme 173: Rh(III)-catalyzed mechanistic pathway.
Scheme 174: Rh(III)-mediated oxidative coupling reaction.
Scheme 175: Reactions showing functionalization of the product obtained by the group of Kotla.
Scheme 176: Mechanism for Rh(III)-catalyzed oxidative coupling reaction.
Scheme 177: Rh(III)-catalyzed C–H activation reaction.
Scheme 178: Mechanistic cycle.
Scheme 179: Annulation reactions of 2-arylimidazo[1,2-a]pyridines and alkynes.
Scheme 180: Two-way reaction mechanism for annulations reaction.
Scheme 181: [RuCl2(p-cymene)]2-catalyzed C–C bond formation reaction.
Scheme 182: Reported reaction mechanism.
Scheme 183: Fe(III) catalyzed C-3 formylation approach.
Scheme 184: SET mechanism-catalyzed by Fe(III).
Scheme 185: Ni(dpp)Cl2-catalyzed KTC coupling.
Scheme 186: Pd-catalyzed SM coupling.
Scheme 187: Vanadium-catalyzed coupling of IP and NMO.
Scheme 188: Mechanistic cycle.
Scheme 189: Selective C3/C5–H bond functionalizations by mono and bimetallic systems.
Scheme 190: rGO-Ni@Pd-catalyzed C–H bond arylation of imidazo[1,2-a]pyridine.
Scheme 191: Mechanistic pathway for heterogeneously catalyzed arylation reaction.
Scheme 192: Zinc triflate-catalyzed coupling reaction of substituted propargyl alcohols.
Beilstein J. Org. Chem. 2019, 15, 521–534, doi:10.3762/bjoc.15.46
Graphical Abstract
Scheme 1: Selectivity levels found in multiple multicomponent reactions. I) Innate selectivity; II) sequentia...
Scheme 2: Indiscriminate double Ugi MCR upon pyridine-2,6-dicarboxylic acid.
Scheme 3: Representative examples of MCR-polymer synthesis. A) Biginelli HTS of polymers; B) Passerini;- C) U...
Scheme 4: Concept of multicomponent macrocyclization.
Scheme 5: Supramolecular structures out of MMCR macrocyclizations.
Scheme 6: Macrocyclization by MMCRs. A) Staudinger MCR; B) boronic-imine MCR.
Scheme 7: Selective Sequential MMCRs. A and B) MCRs involving terephthalaldehyde; C) Multiple GBB processes w...
Scheme 8: Biased substrates for selective MMCRs.
Scheme 9: The Union concept. A) Asinger–Ugi combination; B) Passerini–Ugi/azide from anthranilic acid; C) Pas...
Scheme 10: Relevant examples of consecutive MCRs exploiting the Union Concept. A) Petasis-Ugi combination; B) ...
Scheme 11: Selective MMCRs featuring FGs with distinct reactivity along the sequence. A) Synthesis of aminomet...
Scheme 12: High order MMCRs. A) Ugi/Ugi–Smiles 7C combination; B) imidazoline-N-cyanomethylamide-Ugi union lea...
Scheme 13: Consecutive Ugi 4CR-deprotection–Ugi 4CR strategy towards A) PNA oligomers and B) peptidic tetrazol...
Scheme 14: Sequential Ugi 4CR-deprotection access to cyclopeptoids.
Scheme 15: Stepwise access to 6-aminopenicillanic acid derivative through an Asinger, deprotection, Joullié ap...
Scheme 16: A triple MCR-deprotection approach affording anticancer peptidomimetics.
Beilstein J. Org. Chem. 2018, 14, 1208–1214, doi:10.3762/bjoc.14.102
Graphical Abstract
Figure 1: Bioactive compounds with pyridinone, quinolone and indole cores.
Scheme 1: C–H functionalization of pyridinones and quinoline N-oxides.
Scheme 2: Scope and limitations of the Rh-catalyzed C–H activation of [1,2'-bipyridin]-2-one.
Scheme 3: Scope of the Rh-catalyzed peri C–H activation of quinoline N-oxides.
Scheme 4: Product modifications.
Beilstein J. Org. Chem. 2016, 12, 1647–1748, doi:10.3762/bjoc.12.162
Graphical Abstract
Figure 1: The named transformations considered in this review.
Scheme 1: The Baeyer–Villiger oxidation.
Scheme 2: The general mechanism of the peracid-promoted Baeyer–Villiger oxidation.
Scheme 3: General mechanism of the Lewis acid-catalyzed Baeyer–Villiger rearrangement.
Scheme 4: The theoretically studied mechanism of the BV oxidation reaction promoted by H2O2 and the Lewis aci...
Scheme 5: Proton movements in the transition states of the Baeyer–Villiger oxidation.
Scheme 6: The dependence of the course of the Baeyer–Villiger oxidation on the type of O–O-bond cleavage in t...
Scheme 7: The acid-catalyzed Baeyer–Villiger oxidation of cyclic epoxy ketones 22.
Scheme 8: Oxidation of isophorone oxide 29.
Scheme 9: Synthesis of acyl phosphate 32 from acyl phosphonate 31.
Scheme 10: Synthesis of aflatoxin B2 (36).
Scheme 11: The Baeyer–Villiger rearrangement of ketones 37 to lactones 38.
Scheme 12: Synthesis of 3,4-dimethoxybenzoic acid (40) via Baeyer–Villiger oxidation.
Scheme 13: Oxone transforms α,β-unsaturated ketones 43 into vinyl acetates 44.
Scheme 14: The Baeyer–Villiger oxidation of ketones 45 using diaryl diselenide and hydrogen peroxide.
Scheme 15: Baeyer–Villiger oxidation of (E)-2-methylenecyclobutanones.
Scheme 16: Oxidation of β-ionone (56) by H2O2/(BnSe)2 with formation of (E)-2-(2,6,6-trimethylcyclohex-1-en-1-...
Scheme 17: The mechanism of oxidation of ketones 58a–f by hydrogen peroxide in the presence of arsonated polys...
Scheme 18: Oxidation of ketone (58b) by H2O2 to 6-methylcaprolactone (59b) catalyzed by Pt complex 66·BF4.
Scheme 19: Oxidation of ketones 67 with H2O2 in the presence of [(dppb}Pt(µ-OH)]22+.
Scheme 20: The mechanism of oxidation of ketones 67 in the presence of [(dppb}Pt(µ-OH)]22+ and H2O2.
Scheme 21: Oxidation of benzaldehydes 69 in the presence of the H2O2/MeReO3 system.
Scheme 22: Oxidation of acetophenones 72 in the presence of the H2O2/MeReO3 system.
Scheme 23: Baeyer–Villiger oxidation of 2-adamantanone (45c) in the presence of Sn-containing mesoporous silic...
Scheme 24: Aerobic Baeyer–Villiger oxidation of ketones 76 using metal-free carbon.
Scheme 25: A regioselective Baeyer-Villiger oxidation of functionalized cyclohexenones 78 into a dihydrooxepin...
Scheme 26: The oxidation of aldehydes and ketones 80 by H2O2 catalyzed by Co4HP2Mo15V3O62.
Scheme 27: The cleavage of ketones 82 with hydrogen peroxide in alkaline solution.
Scheme 28: Oxidation of ketones 85 to esters 86 with H2O2–urea in the presence of KHCO3.
Scheme 29: Mechanism of the asymmetric oxidation of cyclopentane-1,2-dione 87a with the Ti(OiPr)4/(+)DET/t-BuO...
Scheme 30: The oxidation of cis-4-tert-butyl-2-fluorocyclohexanone (93) with m-chloroperbenzoic acid.
Scheme 31: The mechanism of the asymmetric oxidation of 3-substituted cyclobutanone 96a in the presence of chi...
Scheme 32: Enantioselective Baeyer–Villiger oxidation of cyclic ketones 98.
Scheme 33: Regio- and enantioselective Baeyer–Villiger oxidation of cyclic ketones 101.
Scheme 34: The proposed mechanism of the Baeyer–Villiger oxidation of acetal 105f.
Scheme 35: Synthesis of hydroxy-10H-acridin-9-one 117 from tetramethoxyanthracene 114.
Scheme 36: The Baeyer–Villiger oxidation of the fully substituted pyrrole 120.
Scheme 37: The Criegee rearrangement.
Scheme 38: The mechanism of the Criegee reaction of a peracid with a tertiary alcohol 122.
Scheme 39: Criegee rearrangement of decaline ethylperoxoate 127 into ketal 128.
Scheme 40: The ionic cleavage of 2-methoxy-2-propyl perester 129.
Scheme 41: The Criegee rearrangement of α-methoxy hydroperoxide 136.
Scheme 42: Synthesis of enol esters and acetals via the Criegee rearrangement.
Scheme 43: Proposed mechanism of the transformation of 1-hydroperoxy-2-oxabicycloalkanones 147a–d.
Scheme 44: Transformation of 3-hydroxy-1,2-dioxolanes 151 into diketone derivatives 152.
Scheme 45: Criegee rearrangement of peroxide 153 with the mono-, di-, and tri-O-insertion.
Scheme 46: The sequential Criegee rearrangements of adamantanes 157a,b.
Scheme 47: Synthesis of diaryl carbonates 160a–d from triarylmethanols 159a–d through successive oxygen insert...
Scheme 48: The synthesis of sesquiterpenes 162 from ketone 161 with a Criegee rearrangement as one key step.
Scheme 49: Synthesis of trans-hydrindan derivatives 164, 165.
Scheme 50: The Hock rearrangement.
Scheme 51: The general scheme of the cumene process.
Scheme 52: The Hock rearrangement of aliphatic hydroperoxides.
Scheme 53: The mechanism of solvolysis of brosylates 174a–c and spiro cyclopropyl carbinols 175a–c in THF/H2O2....
Scheme 54: The fragmentation mechanism of hydroperoxy acetals 178 to esters 179.
Scheme 55: The acid-catalyzed rearrangement of phenylcyclopentyl hydroperoxide 181.
Scheme 56: The peroxidation of tertiary alcohols in the presence of a catalytic amount of acid.
Scheme 57: The acid-catalyzed reaction of bicyclic secondary alcohols 192 with hydrogen peroxide.
Scheme 58: The photooxidation of 5,6-disubstituted 3,4-dihydro-2H-pyrans 196.
Scheme 59: The oxidation of tertiary alcohols 200a–g, 203a,b, and 206.
Scheme 60: Transformation of functional peroxide 209 leading to 2,3-disubstitued furans 210 in one step.
Scheme 61: The synthesis of carbazoles 213 via peroxide rearrangement.
Scheme 62: The construction of C–N bonds using the Hock rearrangement.
Scheme 63: The synthesis of moiety 218 from 217 which is a structural motif in the antitumor–antibiotic of CC-...
Scheme 64: The in vivo oxidation steps of cholesterol (219) by singlet oxygen.
Scheme 65: The proposed mechanism of the rearrangement of cholesterol-5α-OOH 220.
Scheme 66: Photochemical route to artemisinin via Hock rearrangement of 223.
Scheme 67: The Kornblum–DeLaMare rearrangement.
Scheme 68: Kornblum–DeLaMare transformation of 1-phenylethyl tert-butyl peroxide (225).
Scheme 69: The synthesis 4-hydroxyenones 230 from peroxide 229.
Scheme 70: The Kornblum–DeLaMare rearrangement of peroxide 232.
Scheme 71: The reduction of peroxide 234.
Scheme 72: The Kornblum–DeLaMare rearrangement of endoperoxide 236.
Scheme 73: The rearrangement of peroxide 238 under Kornblum–DeLaMare conditions.
Scheme 74: The proposed mechanism of rearrangement of peroxide 238.
Scheme 75: The Kornblum–DeLaMare rearrangement of peroxides 242a,b.
Scheme 76: The base-catalyzed rearrangements of bicyclic endoperoxides having electron-withdrawing substituent...
Scheme 77: The base-catalyzed rearrangements of bicyclic endoperoxides 249a,b having electron-donating substit...
Scheme 78: The base-catalyzed rearrangements of bridge-head substituted bicyclic endoperoxides 251a,b.
Scheme 79: The Kornblum–DeLaMare rearrangement of hydroperoxide 253.
Scheme 80: Synthesis of β-hydroxy hydroperoxide 254 from endoperoxide 253.
Scheme 81: The amine-catalyzed rearrangement of bicyclic endoperoxide 263.
Scheme 82: The base-catalyzed rearrangement of meso-endoperoxide 268 into 269.
Scheme 83: The photooxidation of 271 and subsequent Kornblum–DeLaMare reaction.
Scheme 84: The Kornblum–DeLaMare rearrangement as one step in the oxidation reaction of enamines.
Scheme 85: The Kornblum–DeLaMare rearrangement of 3,5-dihydro-1,2-dioxenes 284, 1,2-dioxanes 286, and tert-but...
Scheme 86: The Kornblum–DeLaMare rearrangement of epoxy dioxanes 290a–d.
Scheme 87: Rearrangement of prostaglandin H2 292.
Scheme 88: The synthesis of epicoccin G (297).
Scheme 89: The Kornblum–DeLaMare rearrangement used in the synthesis of phomactin A.
Scheme 90: The Kornblum–DeLaMare rearrangement in the synthesis of 3H-quinazolin-4-one 303.
Scheme 91: The Kornblum–DeLaMare rearrangement in the synthesis of dolabriferol (308).
Scheme 92: Sequential transformation of 3-substituted 2-pyridones 309 into 3-hydroxypyridine-2,6-diones 311 in...
Scheme 93: The Kornblum–DeLaMare rearrangement of peroxide 312 into hydroxy enone 313.
Scheme 94: The Kornblum–DeLaMare rearrangement in the synthesis of polyfunctionalized carbonyl compounds 317.
Scheme 95: The Kornblum–DeLaMare rearrangement in the synthesis of (Z)-β-perfluoroalkylenaminones 320.
Scheme 96: The Kornblum–DeLaMare rearrangement in the synthesis of γ-ketoester 322.
Scheme 97: The Kornblum–DeLaMare rearrangement in the synthesis of diterpenoids 326 and 328.
Scheme 98: The synthesis of natural products hainanolidol (331) and harringtonolide (332) from peroxide 329.
Scheme 99: The synthesis of trans-fused butyrolactones 339 and 340.
Scheme 100: The synthesis of leucosceptroid C (343) and leucosceptroid P (344) via the Kornblum–DeLaMare rearra...
Scheme 101: The Dakin oxidation of arylaldehydes or acetophenones.
Scheme 102: The mechanism of the Dakin oxidation.
Scheme 103: A solvent-free Dakin reaction of aromatic aldehydes 356.
Scheme 104: The organocatalytic Dakin oxidation of electron-rich arylaldehydes 358.
Scheme 105: The Dakin oxidation of electron-rich arylaldehydes 361.
Scheme 106: The Dakin oxidation of arylaldehydes 358 in water extract of banana (WEB).
Scheme 107: A one-pot approach towards indolo[2,1-b]quinazolines 364 from indole-3-carbaldehydes 363 through th...
Scheme 108: The synthesis of phenols 367a–c from benzaldehydes 366a-c via acid-catalyzed Dakin oxidation.
Scheme 109: Possible transformation paths of the highly polarized boric acid coordinated H2O2–aldehyde adduct 3...
Scheme 110: The Elbs oxidation of phenols 375 to hydroquinones.
Scheme 111: The mechanism of the Elbs persulfate oxidation of phenols 375 affording p-hydroquinones 376.
Scheme 112: Oxidation of 2-pyridones 380 under Elbs persulfate oxidation conditions.
Scheme 113: Synthesis of 3-hydroxy-4-pyridone (384) via an Elbs oxidation of 4-pyridone (382).
Scheme 114: The Schenck rearrangement.
Scheme 115: The Smith rearrangement.
Scheme 116: Three main pathways of the Schenck rearrangement.
Scheme 117: The isomerization of hydroperoxides 388 and 389.
Scheme 118: Trapping of dioxacyclopentyl radical 392 by oxygen.
Scheme 119: The hypothetical mechanism of the Schenck rearrangement of peroxide 394.
Scheme 120: The autoxidation of oleic acid (397) with the use of labeled isotope 18O2.
Scheme 121: The rearrangement of 18O-labeled hydroperoxide 400 under an atmosphere of 16O2.
Scheme 122: The rearrangement of the oleate-derived allylic hydroperoxides (S)-421 and (R)-425.
Scheme 123: Mechanisms of Schenck and Smith rearrangements.
Scheme 124: The rearrangement and cyclization of 433.
Scheme 125: The Wieland rearrangement.
Scheme 126: The rearrangement of bis(triphenylsilyl) 439 or bis(triphenylgermyl) 441 peroxides.
Scheme 127: The oxidative transformation of cyclic ketones.
Scheme 128: The hydroxylation of cyclohexene (447) in the presence of tungstic acid.
Scheme 129: The oxidation of cyclohexene (447) under the action of hydrogen peroxide.
Scheme 130: The reaction of butenylacetylacetone 455 with hydrogen peroxide.
Scheme 131: The oxidation of bridged 1,2,4,5-tetraoxanes.
Scheme 132: The proposed mechanism for the oxidation of bridged 1,2,4,5-tetraoxanes.
Scheme 133: The rearrangement of ozonides.
Scheme 134: The acid-catalyzed oxidative rearrangement of malondialdehydes 462 under the action of H2O2.
Scheme 135: Pathways of the Lewis acid-catalyzed cleavage of dialkyl peroxides 465 and ozonides 466.
Scheme 136: The mechanism of the transformation of (tert-butyldioxy)cyclohexanedienones 472.
Scheme 137: The synthesis of Vitamin K3 from 472a.
Scheme 138: Proposed mechanism for the transformation of 478d into silylated endoperoxide 479d.
Scheme 139: The rearrangement of hydroperoxide 485 to form diketone 486.
Scheme 140: The base-catalyzed rearrangement of cyclic peroxides 488a–g.
Scheme 141: Synthesis of chiral epoxides and aldols from peroxy hemiketals 491.
Scheme 142: The multistep transformation of (R)-carvone (494) to endoperoxides 496a–e.
Scheme 143: The decomposition of anthracene endoperoxide 499.
Scheme 144: Synthesis of esters 503 from aldehydes 501 via rearrangement of peroxides 502.
Scheme 145: Two possible paths for the base-promoted decomposition of α-azidoperoxides 502.
Scheme 146: The Story decomposition of cyclic diperoxide 506a.
Scheme 147: The Story decomposition of cyclic triperoxide 506b.
Scheme 148: The thermal rearrangement of endoperoxides A into diepoxides B.
Scheme 149: The transformation of peroxide 510 in the synthesis of stemolide (511).
Scheme 150: The possible mechanism of the rearrangement of endoperoxide 261g.
Scheme 151: The photooxidation of indene 517.
Scheme 152: The isomerization of ascaridole (523).
Scheme 153: The isomerization of peroxide 525.
Scheme 154: The thermal transformation of endoperoxide 355.
Scheme 155: The photooxidation of cyclopentadiene (529) at a temperature higher than 0 °C.
Scheme 156: The thermal rearrangement of endoperoxides 538a,b.
Scheme 157: The transformation of peroxides 541.
Scheme 158: The thermal rearrangements of strained cyclic peroxides.
Scheme 159: The thermal rearrangement of diacyl peroxide 551 in the synthesis of C4-epi-lomaiviticin B core 553....
Scheme 160: The 1O2 oxidation of tryptophan (554) and rearrangement of dioxetane intermediate 555.
Scheme 161: The Fe(II)-promoted cleavage of aryl-substituted bicyclic peroxides.
Scheme 162: The proposed mechanism of the Fe(II)-promoted rearrangement of 557a–c.
Scheme 163: The reaction of dioxolane 563 with Fe(II) sulfate.
Scheme 164: Fe(II)-promoted rearrangement of 1,2-dioxane 565.
Scheme 165: Fe(II) cysteinate-promoted rearrangement of 1,2-dioxolane 568.
Scheme 166: The transformation of 1,2-dioxanes 572a–c under the action of FeCl2.
Scheme 167: Fe(II) cysteinate-promoted transformation of tetraoxane 574.
Scheme 168: The CoTPP-catalyzed transformation of bicyclic endoperoxides 600a–d.
Scheme 169: The CoTPP-catalyzed transformation of epoxy-1,2-dioxanes.
Scheme 170: The Ru(II)-catalyzed reactions of 1,4-endoperoxide 261g.
Scheme 171: The Ru(II)-catalyzed transformation as a key step in the synthesis of elyiapyrone A (610) from 1,4-...
Scheme 172: Peroxides with antimalarial activity.
Scheme 173: The interaction of iron ions with artemisinin (616).
Scheme 174: The interaction of FeCl2 with 1,2-dioxanes 623, 624.
Scheme 175: The mechanism of reaction 623 and 624 with Fe(II)Cl2.
Scheme 176: The reaction of bicyclic natural endoperoxides G3-factors 631–633 with FeSO4.
Scheme 177: The transformation of terpene cardamom peroxide 639.
Scheme 178: The different ways of the cleavage of tetraoxane 643.
Scheme 179: The LC–MS analysis of interaction of tetraoxane 646 with iron(II)heme 647.
Scheme 180: The rearrangement of 3,6-epidioxy-1,10-bisaboladiene (EDBD, 649).
Scheme 181: Easily oxidized substrates.
Scheme 182: Biopathway of synthesis of prostaglandins.
Scheme 183: The reduction and rearrangements of isoprostanes.
Scheme 184: The partial mechanism for linoleate 658 oxidation.
Scheme 185: The transformation of lipid hydroperoxide.
Scheme 186: The acid-catalyzed cleavage of the product from free-radical oxidation of cholesterol (667).
Scheme 187: Two pathways of catechols oxidation.
Scheme 188: Criegee-like or Hock-like rearrangement of the intermediate hydroperoxide 675 in dioxygenase enzyme...
Scheme 189: Carotinoides 679 cleavage by carotenoid cleavage dioxygenases.
Beilstein J. Org. Chem. 2016, 12, 1512–1550, doi:10.3762/bjoc.12.148
Graphical Abstract
Scheme 1: Schematic description of the cyclisation reaction catalysed by TE domains. In most cases, the nucle...
Scheme 2: Mechanisms for the formation of oxygen heterocycles. The degree of substitution can differ from tha...
Scheme 3: Pyran-ring formation in pederin (24) biosynthesis. Incubation of recombinant PedPS7 with substrate ...
Scheme 4: The domain AmbDH3 from ambruticin biosynthesis catalyses the dehydration of 25 and subsequent cycli...
Scheme 5: SalBIII catalyses dehydration of 29 and subsequent cyclisation to tetrahydropyran 30 [18].
Figure 1: All pyranonaphtoquinones contain either the naphtha[2,3-c]pyran-5,10-dione (32) or the regioisomeri...
Scheme 6: Pyran-ring formation in actinorhodin (34) biosynthesis. DNPA: 4-dihydro-9-hydroxy-1-methyl-10-oxo-3H...
Scheme 7: Pyran formation in granaticin (36) biosynthesis. DNPA: 4-dihydro-9-hydroxy-1-methyl-10-oxo-3H-napht...
Scheme 8: Pyran formation in alnumycin (37) biosynthesis. Adapted from [21].
Scheme 9: Biosynthesis of pseudomonic acid A (61). The pyran ring is initially formed in 57 after dehydrogena...
Scheme 10: Epoxidation–cyclisation leads to the formation of the tetrahydropyran ring in the western part of t...
Scheme 11: a) Nonactin (70) is formed from heterodimers of (−)(+)-dimeric nonactic acid and (+)(−)-dimeric non...
Figure 2: Pamamycins (73) are macrodiolide antibiotics containing three tetrahydrofuran moieties, which are a...
Scheme 12: A PS domain homolog in oocydin A (76) biosynthesis is proposed to catalyse furan formation via an o...
Scheme 13: Mechanism of oxidation–furan cyclisation by AurH, which converts (+)-deoxyaureothin (77) into (+)-a...
Scheme 14: Leupyrrin A2 (80) and the proposed biosynthesis of its furylidene moiety [69,70].
Scheme 15: Asperfuranone (93) biosynthesis, adapted from [75].
Figure 3: The four major aflatoxins produced by Aspergilli are the types B1, B2, G1 and G2 (94–97). In the di...
Scheme 16: Overview on aflatoxin B1 (94) biosynthesis. HOMST = 11-hydroxy-O-methylsterigmatocystin [78,79,82-106].
Scheme 17: A zipper mechanism leads to the formation of oxygen heterocycles in monensin biosynthesis [109-111].
Scheme 18: Formation of the 2,6-dioxabicyclo[3.2.1]octane (DBO) ring system in aurovertin B (118) biosynthesis ...
Figure 4: Structures of the epoxide-containing polyketides epothilone A (119) and oleandomycin (120) [123-125].
Scheme 19: Structures of phoslactomycin B (121) (a) and jerangolid A (122) (b). The heterocycle-forming steps ...
Scheme 20: a) Structures of rhizoxin (130) and cycloheximide (131). Model for the formation of δ-lactones (b) ...
Scheme 21: EncM catalyses a dual oxidation sequence and following processing of the highly reactive intermedia...
Figure 5: Mesomeric structures of tetronates [138,139].
Figure 6: Structures of tetronates for which gene clusters have been sequenced. The tetronate moiety is shown...
Scheme 22: Conserved steps for formation and processing in several 3-acyl-tetronate biosynthetic pathways were...
Scheme 23: In versipelostatin A (153) biosynthesis, VstJ is a candidate enzyme for catalysing the [4 + 2] cycl...
Scheme 24: a) Structures of some thiotetronate antibiotics. b) Biosynthesis of thiolactomycin (165) as propose...
Scheme 25: Aureusidine synthase (AS) catalyses phenolic oxidation and conjugate addition of chalcones leading ...
Scheme 26: a) Oxidative cyclisation is a key step in the biosynthesis of spirobenzofuranes 189, 192 and 193. b...
Scheme 27: A bicyclisation mechanism forms a β-lactone and a pyrrolidinone and removes the precursor from the ...
Scheme 28: Spontaneous cyclisation leads to off-loading of ebelactone A (201) from the PKS machinery [163].
Scheme 29: Mechanisms for the formation of nitrogen heterocycles.
Scheme 30: Biosynthesis of highly substituted α-pyridinones. a) Feeding experiments confirmed the polyketide o...
Scheme 31: Acridone synthase (ACS) catalyses the formation of 1,3-dihydroxy-N-methylacridone (224) by condensa...
Scheme 32: A Dieckmann condensation leads to the formation of a 3-acyl-4-hydroxypyridin-2-one 227 and removes ...
Scheme 33: a) Biosynthesis of the pyridinone tenellin (234). b) A radical mechanism was proposed for the ring-...
Scheme 34: a) Oxazole-containing PKS–NRPS-derived natural products oxazolomycin (244) and conglobatin (245). b...
Scheme 35: Structure of tetramic acids 251 (a) and major tautomers of 3-acyltetramic acids 252a–d (b). Adapted...
Scheme 36: Equisetin biosynthesis. R*: terminal reductive domain. Adapted from [202].
Scheme 37: a) Polyketides for which a similar biosynthetic logic was suggested. b) Pseurotin A (256) biosynthe...
Figure 7: Representative examples of PTMs with varying ring sizes and oxidation patterns [205,206].
Scheme 38: Ikarugamycin biosynthesis. Adapted from [209-211].
Scheme 39: Tetramate formation in pyrroindomycin aglycone (279) biosynthesis [213-215].
Scheme 40: Dieckmann cyclases catalyse tetramate or 2-pyridone formation in the biosynthesis of, for example, ...
Beilstein J. Org. Chem. 2016, 12, 1170–1177, doi:10.3762/bjoc.12.112
Graphical Abstract
Scheme 1: Synthesis of highly functionalized 2,2'-bipyridines 4a and 5b from symmetrical 1,3-diketones 1a and ...
Scheme 2: Synthesis of β-ketoenamines 2c–e and of β-ketoenamides 3c–h.
Scheme 3: Synthesis of α-methoxy-β-ketoenamine 2i, its N-acylation to 3i and the reaction of β-ketoenamide 3a...
Scheme 4: Cyclizations of β-ketoenamide 3i leading to 2,2´-bipyridine derivative 4i or to the related 2-(2-py...
Scheme 5: Suzuki-couplings of 2,2'-bipyrid-4-yl nonaflates 5a and 5b to compounds 9 and 10.
Scheme 6: Palladium-catalyzed couplings of chloro-substituted 2,2'-bipyrid-4-yl nonaflate 5g leading to compo...